Target Name: GYPA
NCBI ID: G2993
Review Report on GYPA Target / Biomarker Content of Review Report on GYPA Target / Biomarker
GYPA
Other Name(s): OTTHUMP00000220159 | sialoglycoprotein alpha | HGpMiXI | GLPA_HUMAN | Glycophorin SAT | Glycophorin-A | Sialoglycoprotein alpha | Glycophorin A (MNS blood group), transcript variant 1 | PAS-2 | erythroid-lineage-specific membrane sialoglycoprotein | Glycophorin Sta type C | OTTHUMP00000220158 | glycophorin Sta type C | recombinant glycophorin A-B Miltenberger-DR | Glycophorin MiIII | glycophorin A (MN blood group) | Erythroid-lineage-specific membrane sialoglycoprotein | Glycophorin A | GpMiIII | Glycophorin MiI | glycophorin MiI | glycophorin A (MNS blood group) | CD235a | HGpMiX | HGpSta(C) | MN sialoglycoprotein | MNS | HGpMiV | GYPA variant 1 | Recombinant glycophorin A-B Miltenberger-DR | MN | glycophorin Erik | HGpMiIII | GPA | glycophorin SAT | glycophorin MiV | Glycophorin MiX | Glycophorin MiV | Glycophorin Erik | Glycophorin-A (isoform 1) | Glycophorin A, GPA | Glycophorin A (MN blood group) | glycophorin A, GPA | Mi.V glycoprotein (24 AA) | OTTHUMP00000220156 | GPSAT | GPErik | OTTHUMP00000220154

GYPA: A Potential Drug Target and Research Tool

GYPA (Glycophosphorylase A) is a protein that is expressed in various tissues throughout the body, including muscle, heart, and brain. It is a key enzyme in the phosphorylcholine cycle, a process that is involved in the synthesis of the neurotransmitter acetylcholine. GYPA is also involved in the synthesis of other important molecules, including neurotransmitters such as dopamine and GABA.

GYPA is a potential drug target for several reasons. Firstly, GYPA is involved in the synthesis of a neurotransmitter that is involved in many important physiological processes, making it an attractive target for drug development. Secondly, GYPA is a strong candidate for a drug target because it is a transmembrane protein, which means that it is expressed in the cell membrane and is accessible to small molecules that can interact with it. This makes it easier for drugs to interact with GYPA and potentially block its activity.

GYPA is also a good candidate for a drug target because it is a validated drug target. Several drugs that have been developed to block GYPA have been shown to be effective in treating various neurological and psychiatric disorders. For example, inhibitors of GYPA have been shown to be effective in treating symptoms of Alzheimer's disease, Parkinson's disease, and depression.

In addition to its potential therapeutic uses, GYPA is also a valuable research tool. Because it is a protein that is expressed in many different tissues, researchers have been able to use it as a tool to study the underlying biology of a wide range of cellular processes. This has led to a greater understanding of the role that GYPA plays in these processes, as well as the potential mechanisms by which it functions.

Overall, GYPA is a protein that is worth studying as a potential drug target. Its involvement in the synthesis of important neurotransmitters, its accessibility to small molecules, and its role as a validated drug target make it an attractive target for drug development. Additionally, Its role as a research tool makes it a valuable tool for studying the underlying biology of cellular processes.

Protein Name: Glycophorin A (MNS Blood Group)

Functions: Glycophorin A is the major intrinsic membrane protein of the erythrocyte. The N-terminal glycosylated segment, which lies outside the erythrocyte membrane, has MN blood group receptors. Appears to be important for the function of SLC4A1 and is required for high activity of SLC4A1. May be involved in translocation of SLC4A1 to the plasma membrane. Is a receptor for influenza virus. Is a receptor for Plasmodium falciparum erythrocyte-binding antigen 175 (EBA-175); binding of EBA-175 is dependent on sialic acid residues of the O-linked glycans. Appears to be a receptor for Hepatitis A virus (HAV)

The "GYPA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GYPA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37